Investigational compounds and registered medicines have different regulatory statuses. Retatrutide is investigational and is not ARTG-registered. Registered tirzepatide products use standard prescriptions.
Compounded GLP-1 medicines cannot be legally supplied since 1 October 2024. Only TGA-approved registered products are available on prescription. Evidence limitations, interactions and individual safety require clinical assessment. Research-vendor products cannot establish quality or lawful access.
An investigational compound is still being studied in clinical trials. Its benefits, side effects and long-term safety are not fully known, and it has not been assessed by the TGA for supply in Australia. Outside an approved clinical trial, there is generally no lawful way to obtain it.
A registered medicine has been evaluated by the TGA for quality, safety and efficacy for the conditions listed in its approved product information. It is entered on the Australian Register of Therapeutic Goods, and a prescription-only medicine is dispensed by a pharmacist on a valid prescription.
Published trial data describe a specific, quality-controlled product used under medical supervision in selected participants. Products sold online as research chemicals have none of those controls, and the TGA has warned that their contents may not match the label. Trial headlines don't transfer to those products.
Some people take part in clinical trials of investigational medicines. Trials are approved by ethics committees and run under strict protocols. The Australian Clinical Trials website lists recruiting studies, and a GP can help you work out whether a trial is relevant to you.
If you're comparing options, a registered doctor can explain which medicines are approved in Australia, what the evidence shows, the known side effects, and whether any approved option is suitable for you. Supply, cost and eligibility rules can change, so check current TGA information. This article is general information only.
Media reports about new medicines often describe average changes seen in trial groups. Those averages don't predict what will happen for any one person, and trial participants are screened, monitored and supported in ways that ordinary use is not. Findings from early-phase trials can also change as larger studies report. When reading about an investigational compound, look for the trial phase, the number of participants, how long they were followed, and which side effects led people to stop. Peer-reviewed publications and regulator statements are more reliable than summaries on seller or social media sites.
The TGA also publishes safety alerts and recalls on its website, and they are worth checking before relying on any claim you read online.